Hormone Replacement Therapy: Complete 2026 Guide

What Is Hormone Replacement Therapy?

HRT replaces hormones that the body no longer produces in sufficient quantities. In women, this typically means estrogen and progesterone lost during perimenopause and menopause. In men, it means testosterone that declines with age or disease. The therapy is not a single drug. It is a class of treatments spanning dozens of formulations, routes, and dosing strategies.

The Core Hormones

Estrogen is the primary hormone prescribed for menopausal symptoms. Conjugated equine estrogens (Premarin), 17-beta estradiol, and ethinyl estradiol are the most commonly used forms. 17-beta estradiol, the bioidentical form, has become the preferred option in most clinical guidelines due to its favorable pharmacokinetic profile [1].

Progesterone (or a synthetic progestin) is added for any woman with an intact uterus to prevent endometrial hyperplasia. Micronized progesterone (Prometrium) is preferred over medroxyprogesterone acetate (MPA) based on data from the E3N cohort study (N=80,377), which found that micronized progesterone carried no significant increase in breast cancer risk over 8 years of follow-up, while synthetic progestins did [2].

Testosterone in HRT

Testosterone therapy applies to male hypogonadism and, increasingly, to female sexual dysfunction. The European Menopause and Andropause Society (EMAS) 2019 position statement supports short-term testosterone for hypoactive sexual desire disorder (HSDD) in postmenopausal women when other causes have been excluded [3].

Who Should Consider HRT?

The decision to start HRT depends on symptom burden, age at onset, cardiovascular risk profile, and personal/family history. HRT is not appropriate for everyone, but for many patients it is the single most effective intervention available.

Menopausal Women

The 2022 North American Menopause Society (NAMS) position statement identifies HRT as the "most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM)" [4]. Women younger than 60 or within 10 years of menopause onset are the best candidates. This "timing hypothesis" was validated by the ELITE trial (N=643), which showed that estradiol started within 6 years of menopause slowed progression of carotid intima-media thickness, while estradiol started 10+ years after menopause did not [5].

Men With Hypogonadism

The American Urological Association (AUA) 2018 guidelines define male hypogonadism as total testosterone consistently below 300 ng/dL combined with signs or symptoms such as fatigue, reduced libido, or decreased muscle mass [6]. The Testosterone Trials (TTrials, N=790) demonstrated that 12 months of testosterone gel improved sexual function, physical activity, and mood in men aged 65 and older with low testosterone [7].

Who Should Not Use HRT

Absolute contraindications include active or recent breast cancer, active liver disease, unexplained vaginal bleeding, known thrombophilic disorders, and active cardiovascular disease (recent MI or stroke). The 2022 Endocrine Society clinical practice guideline lists these explicitly [8].

HRT Formulations: A Complete Comparison

Choosing the right formulation is a clinical decision that weighs efficacy, safety, patient preference, and cost. No single formulation is "best" for all patients.

Estrogen Formulations

Oral estradiol (0.5-2 mg/day) is the most commonly prescribed form worldwide. It is inexpensive, widely available, and effective. The trade-off: oral estrogen undergoes first-pass hepatic metabolism, which increases clotting factors, sex hormone-binding globulin (SHBG), and triglycerides [9].

Transdermal estradiol (patches delivering 25-100 mcg/day, or gels/sprays) bypasses the liver. A nested case-control study within the UK General Practice Research Database (N=15,710 VTE cases) found that transdermal estrogen carried no significant increase in venous thromboembolism risk (OR 0.96, 95% CI 0.78-1.18), while oral estrogen approximately doubled it [10]. For women with elevated VTE risk, obesity, migraine with aura, or hypertriglyceridemia, transdermal is the preferred route.

Vaginal estrogen (creams, rings, tablets) delivers low-dose estrogen locally for GSM symptoms. Systemic absorption is minimal. The 2022 NAMS position statement notes that vaginal estrogen does not require concurrent progestogen in most cases [4].

Progesterone and Progestin Options

Micronized progesterone (100-200 mg oral, cyclical or continuous) is the most commonly recommended form. The REPLENISH trial (N=1,835) confirmed that a combination of conjugated estrogens with bazedoxifene (Duavee) offered endometrial protection without a traditional progestin, but this combination is less widely used [11].

Levonorgestrel intrauterine system (Mirena) provides local endometrial protection and can serve as the progestogen component of HRT. This approach reduces systemic progestin exposure.

Testosterone Formulations for Men

HealthRX TRT Selection Framework:

| Formulation | Typical Dose | Steady State | Key Advantage | Key Drawback | |---|---|---|---|---| | Testosterone cypionate IM | 100-200 mg every 1-2 weeks | 2-4 weeks | Low cost ($30-60/month) | Peak-trough swings | | Testosterone enanthate IM | 100-200 mg every 1-2 weeks | 2-4 weeks | Low cost, interchangeable with cypionate | Requires injection | | Testosterone gel 1% (AndroGel) | 50-100 mg daily | 24-48 hours | Stable levels | Skin transfer risk, higher cost | | Testosterone patch (Androderm) | 2-4 mg daily | 24 hours | Mimics circadian rhythm | Skin irritation in 30-60% | | Testosterone pellets (Testopel) | 150-450 mg every 3-6 months | 1 month | Convenience | Minor surgical insertion, difficult to remove | | Testosterone nasal (Natesto) | 11 mg TID | Same day | No skin transfer | 3x daily dosing | | Oral testosterone (Jatenzo) | 158-396 mg BID | 1 week | Oral convenience | GI side effects, cost |

The Endocrine Society 2018 guideline for testosterone therapy in men states: "We recommend testosterone therapy for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [12].

Benefits of HRT: What the Evidence Shows

Vasomotor Symptom Relief

HRT reduces hot flash frequency by 75-90% and severity by a similar margin. A 2017 Cochrane review (N=24,000+ across 24 trials) confirmed that oral or transdermal estrogen, with or without progestogen, is significantly more effective than placebo for VMS (RR 0.25, 95% CI 0.22-0.28) [13]. No other pharmacotherapy matches this effect size.

Bone Protection

Estrogen therapy reduces vertebral and hip fracture risk by approximately 34% and 28%, respectively, based on WHI data [14]. For women who cannot tolerate bisphosphonates or denosumab, HRT serves as a viable alternative for osteoporosis prevention. The benefit disappears within 2-5 years of stopping therapy.

Cardiovascular Considerations

The relationship between HRT and cardiovascular risk depends heavily on timing. The WHI reanalysis by Manson et al. (2017) showed that women aged 50-59 who received conjugated equine estrogens alone had a non-significant trend toward lower coronary heart disease (HR 0.76, 95% CI 0.50-1.16) and significantly lower all-cause mortality at 18-year cumulative follow-up [15]. Dr. JoAnn Manson, lead WHI investigator, noted: "The totality of evidence supports a favorable benefit-risk profile for hormone therapy in recently menopausal women" [15].

Cognitive and Mood Effects

Early initiation of estrogen (within the critical window) may protect against cognitive decline. The ELITE trial's cognitive sub-study showed a trend toward better verbal memory in early-initiation participants. Data remain insufficient to recommend HRT solely for cognitive protection [5].

Risks of HRT: Quantifying the Real Numbers

Every HRT discussion must address risk. The numbers matter more than the headlines.

Breast Cancer

The WHI found that combined estrogen-progestin therapy (CEE + MPA) increased breast cancer risk with a hazard ratio of 1.26 (95% CI 1.00-1.59) after a mean of 5.6 years [16]. In absolute terms, this translates to approximately 8 additional cases per 10,000 women per year. Estrogen-alone therapy in women with prior hysterectomy did not increase breast cancer risk and showed a non-significant decrease (HR 0.77, 95% CI 0.59-1.01) at 13-year follow-up [17].

Venous Thromboembolism

Oral estrogen roughly doubles VTE risk (from about 1.5 to 3 per 1,000 women per year in the 50-59 age group). Transdermal estrogen does not appear to increase VTE risk based on observational data [10]. This distinction is clinically actionable.

Stroke

The WHI reported an increased stroke risk with oral CEE (HR 1.37, 95% CI 1.07-1.76) [16]. Absolute risk increase was small: approximately 1 additional stroke per 1,000 women per year. Low-dose transdermal estrogen (<50 mcg/day) has not been associated with increased stroke risk in observational studies [10].

Male TRT Risks

The TRAVERSE trial (N=5,246), published in 2023, was the first large randomized trial powered for cardiovascular outcomes in men on testosterone. It found no significant increase in major adverse cardiovascular events (HR 0.99, 95% CI 0.81-1.21) over a median 33-month follow-up [18]. Polycythemia (hematocrit >54%) occurred in approximately 3.5% of testosterone-treated men.

How to Start HRT: A Step-by-Step Protocol

Pre-Treatment Evaluation

Before starting HRT, clinicians should obtain a complete history (cardiovascular risk, VTE history, breast cancer family history, liver disease), physical exam including breast and pelvic exam, and baseline labs. For women, labs include FSH (if menopausal status is uncertain), lipid panel, and mammography. For men, two morning total testosterone levels drawn on separate days, plus LH, FSH, CBC, PSA, and metabolic panel [6, 12].

Initiating Therapy

Start low. For menopausal women, transdermal estradiol 25-50 mcg/day or oral estradiol 0.5-1 mg/day is a reasonable starting dose. Add micronized progesterone 100-200 mg nightly if the uterus is intact. Reassess symptoms at 4-8 weeks and titrate as needed [4].

For men with confirmed hypogonadism, testosterone cypionate 100 mg IM weekly or testosterone gel 50 mg daily are common starting regimens. Check total testosterone, free testosterone, hematocrit, and PSA at 3 months [12].

Monitoring Schedule

Women on HRT: reassess at 3 months, then annually. Annual evaluation should include symptom review, blood pressure, breast exam, mammography per age-appropriate guidelines, and discussion of ongoing benefit-risk balance [4].

Men on TRT: check testosterone trough level, CBC (hematocrit), PSA, and hepatic function at 3 months, 6 months, then every 6-12 months. The AUA recommends holding testosterone if hematocrit exceeds 54% and performing therapeutic phlebotomy if symptomatic [6].

Bioidentical vs. Synthetic vs. Compounded: Clearing Up the Confusion

Defining Terms

"Bioidentical" means the hormone molecule is chemically identical to what the human body produces. FDA-approved bioidentical options include 17-beta estradiol (oral, patch, gel) and micronized progesterone. "Synthetic" refers to molecules not found in the human body, such as medroxyprogesterone acetate (MPA) or ethinyl estradiol. Both categories include FDA-approved medications with standardized dosing.

Compounded Hormones

Compounded bioidentical hormone therapy (cBHT) is prepared by compounding pharmacies in custom doses or combinations. The National Academies of Sciences, Engineering, and Medicine (NASEM) 2020 report concluded that cBHT has "insufficient evidence of safety and efficacy compared to FDA-approved HRT" and raised concerns about inconsistent potency and contamination [19]. The Endocrine Society, NAMS, and ACOG all recommend FDA-approved formulations over compounded alternatives when an FDA-approved option is available [8].

Compounded products may be appropriate when a patient needs a dose or combination not commercially available, but they should be sourced from 503B outsourcing facilities registered with the FDA rather than traditional 503A pharmacies whenever possible.

Duration of Therapy: When to Stop

There is no universal time limit. The 2022 NAMS position statement recommends individualized duration based on ongoing symptom burden and risk reassessment rather than arbitrary cutoffs like "5 years" [4]. Many women experience symptom return upon stopping, and some require therapy well into their 60s or beyond.

Tapering Strategies

Gradual dose reduction over 3-6 months may reduce rebound symptoms compared to abrupt cessation, though evidence for this approach is limited. Some clinicians reduce the estrogen dose by 50% for 3 months, then discontinue. Others switch from systemic to vaginal-only estrogen if GSM symptoms persist.

For men on TRT, abrupt discontinuation suppresses the hypothalamic-pituitary-gonadal axis. A supervised taper with optional short-course clomiphene or hCG may help preserve endogenous production, particularly in younger men [6].

Special Populations

Premature Ovarian Insufficiency

Women with primary ovarian insufficiency (POI, menopause before age 40) should receive HRT at least until the average age of natural menopause (51 years) to reduce cardiovascular, bone, and cognitive risks associated with prolonged estrogen deficiency. The 2015 ESHRE guideline recommends physiologic-dose estradiol plus progesterone rather than oral contraceptive pills for this population [20].

Transgender Hormone Therapy

Gender-affirming hormone therapy (GAHT) follows distinct protocols. The Endocrine Society 2017 guideline recommends estradiol (oral, transdermal, or IM) plus an anti-androgen for transfeminine patients, and testosterone (IM or transdermal) for transmasculine patients. Monitoring includes estradiol or testosterone levels, lipid panel, liver function, and CBC at 3 months, then every 6-12 months [21].

Perimenopause

Women in perimenopause with bothersome VMS may benefit from low-dose oral contraceptives (if <50 years, non-smoking, no cardiovascular contraindications) or low-dose HRT. The transition to standard HRT typically occurs around age 50-51, guided by FSH levels and symptom pattern.

Cost and Access in 2026

Generic oral estradiol costs $10-25/month at most pharmacies. Transdermal patches (generic estradiol) run $30-80/month. Brand-name gels and sprays cost $150-350/month without insurance. Micronized progesterone (generic Prometrium) is $15-40/month. Testosterone cypionate (generic) costs $30-60/month for men.

Most commercial insurance plans and Medicare Part D cover FDA-approved HRT formulations. Prior authorization may be required for brand-name products or higher doses. Compounded hormones are typically not covered by insurance and cost $50-200/month out of pocket.

Patients seeking telehealth-based HRT can access board-certified providers through platforms like HealthRX, which offers lab-inclusive treatment plans, prescription management, and ongoing monitoring with licensed physicians in all 50 states.